

August 25, 2017



***BUSY WEEK?** Here are the
TOP INDUSTRY NEWS stories
you might have missed, as
selected by DCAT Editorial
Director Patricia Van Arnum.*

1. Stada Shareholders Accept New Takeover Offer

Nidda Healthcare Holding, the acquiring company of Bain Capital and Cinven Partners, has succeeded in a voluntary public takeover of Stada Arzneimittel AG, a Bad Vibel, Germany-based generic and over-the-counter drug company, after reaching the minimum shareholder acceptance threshold of 63%. The offer represents an enterprise value of Stada of EUR 5.4 billion (\$6.3 billion). [Read More](#)

2. President Trump Signs User Fee Bill into Law

President Donald Trump has signed into law the *FDA Reauthorization Act of 2017*, which reauthorizes the FDA to collect user fees for prescription drugs, generic drugs, biosimilars, and medical devices. Current user fees were set to expire September 30, 2017, and the new law authorizes user fees for fiscal year 2018 to fiscal year 2022. [Read More](#)

3. FDA Approves Pfizer's ADC Leukemia Drug

The FDA has approved Pfizer's Besponsa (inotuzumab ozogamicin), an antibody drug conjugate (ADC), for treating adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. This marks the third ADC currently on the market. [Read More](#)

4. Evotec Finalizes \$300-Million Buy of Aptuit

Evotec, a Hamburg, Germany-based drug discovery and development company, has completed its \$300-million acquisition of Aptuit, a pharmaceutical services company. [Read More](#)

5. Ashland Updates Manufacturing Following Fire at German Facility

Ashland updated the impact to its operations as a result of a fire at its manufacturing facility in Marl, Germany. The fire has led to the shutdown of production operations, and the company currently estimates that production will be suspended until late September 2017 at the earliest. [Read More](#)

6. EMA, FDA Expand Information Sharing for Inspections

The FDA, the European Commission, and the European Medicines Agency have signed a new confidentiality commitment that allows US regulators to share non-public and commercially confidential information, including trade-secret information relating to medicine inspections, with regulators from the European Union. [Read More](#)

7. Alembic Sells Formulation Manufacturing Plant

Alembic Pharmaceuticals, a Gujarat, India-based generics pharmaceutical company, has sold its formulation manufacturing plant in Baddi, India to Scott Edil Pharmacia, a Chandigarh, India-based pharmaceutical product manufacturer. [Read More](#)

8. FDA Issues Draft Guidance on Drug Supply Chain Security

The FDA has issued a draft guidance to categorize trading partners in the drug supply chain in accordance with the Drug Supply Chain Security Act (DSCSA). The DSCSA, signed into law in November 2013, provides steps to build an electronic, interoperable system by 2023 that will identify and trace prescription drugs that are distributed within the US. [Read More](#)

9. [Novartis Appoints Chief Digital Officer](#)

Novartis has appointed a chief digital officer for creating and executing a company-wide digital strategy. This is another recent move in which a large pharmaceutical company has appointed a chief digital officer following GlaxoSmithKline in July 2017. [Read More](#)

10. [Takeda, Samsung Bioepis to Co-Develop Biologic Therapies](#)

Takeda Pharmaceutical and Samsung Bioepis, an Incheon, South Korea-headquartered biopharmaceutical company, have agreed to jointly fund and co-develop new biologic therapies. Samsung Bioepis, a joint venture between Samsung BioLogics and Biogen, is also engaged in biosimilar development. [Read More](#)

***The DCAT organization is happy to provide this service to its members each Friday.
Have a great weekend!***

About Top Industry News

The DCAT organization recognizes its members have minimal time to keep up with the continuous flow of news covering this dynamic industry. To help ensure our members never miss the most important stories impacting the global pharmaceutical manufacturing industry, we will deliver each Friday, the week's Top Industry News, as selected by DCAT Editorial Director Patricia Van Arnum.



The Drug, Chemical & Associated Technologies Association (DCAT) is a not-for-profit, global business development association whose unique membership model integrates both innovator and generic drug manufacturers and suppliers of ingredients, development and manufacturing services, and related technologies. We are committed to provide programs, events and services that help our members meet their business objectives, expand their network of customers and suppliers, and gain insight into industry trends, markets, and those issues impacting pharmaceutical development and manufacturing.



One Union Street, Suite 208, Robbinsville, NJ 08691
Local: +1.609.208.1888 · Toll Free: +1.800.640.DCAT(3228) · Fax: +1.609.208.0599
www.dcat.org

Drug, Chemical, & Associated Technologies Association, One Union Street,
Suite 208, Robbinsville, NJ 08691

[SafeUnsubscribe™ {recipient's email}](#)

[Forward this email](#) | [Update Profile](#) | [About our service provider](#)

Sent by dcatnews@dcat.org